Analysts Offer Predictions for United Therapeutics Co.’s Q2 2018 Earnings (UTHR)

United Therapeutics Co. (NASDAQ:UTHR) – Stock analysts at Wedbush lifted their Q2 2018 EPS estimates for United Therapeutics in a report released on Wednesday. Wedbush analyst L. Moussatos now forecasts that the biotechnology company will post earnings per share of $2.82 for the quarter, up from their previous estimate of $2.81. Wedbush has a “Outperform” rating and a $232.00 price objective on the stock. Wedbush also issued estimates for United Therapeutics’ Q3 2018 earnings at $3.07 EPS, Q4 2018 earnings at $2.95 EPS, FY2018 earnings at $12.05 EPS, FY2019 earnings at $11.12 EPS, FY2020 earnings at $11.68 EPS and FY2021 earnings at $11.86 EPS.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.01 by $2.26. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. The business had revenue of $445.50 million during the quarter, compared to analyst estimates of $426.43 million. During the same quarter last year, the firm posted $4.23 earnings per share. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year.

UTHR has been the topic of several other research reports. ValuEngine raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 26th. TheStreet raised shares of United Therapeutics from a “c+” rating to a “b” rating in a report on Friday, December 15th. BidaskClub raised shares of United Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 6th. Zacks Investment Research raised shares of United Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 9th. Finally, Oppenheimer reaffirmed a “buy” rating on shares of United Therapeutics in a report on Friday, September 8th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $138.00.

United Therapeutics (NASDAQ:UTHR) opened at $151.94 on Monday. United Therapeutics has a 12 month low of $112.01 and a 12 month high of $169.89. The company has a market cap of $6,570.00, a P/E ratio of 13.40 and a beta of 1.42.

Several institutional investors and hedge funds have recently made changes to their positions in UTHR. Legal & General Group Plc grew its position in shares of United Therapeutics by 13.5% during the second quarter. Legal & General Group Plc now owns 81,297 shares of the biotechnology company’s stock worth $10,547,000 after acquiring an additional 9,664 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of United Therapeutics by 2.3% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 123,016 shares of the biotechnology company’s stock worth $15,959,000 after acquiring an additional 2,762 shares during the last quarter. Victory Capital Management Inc. grew its position in shares of United Therapeutics by 20.9% during the second quarter. Victory Capital Management Inc. now owns 6,549 shares of the biotechnology company’s stock worth $850,000 after acquiring an additional 1,133 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its position in shares of United Therapeutics by 18.9% during the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 12,764 shares of the biotechnology company’s stock worth $1,656,000 after acquiring an additional 2,025 shares during the last quarter. Finally, Utah Retirement Systems grew its position in shares of United Therapeutics by 1.2% during the second quarter. Utah Retirement Systems now owns 8,165 shares of the biotechnology company’s stock worth $1,060,000 after acquiring an additional 100 shares during the last quarter. Institutional investors and hedge funds own 99.99% of the company’s stock.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 7,061 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $121.12, for a total transaction of $855,228.32. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $122.00, for a total transaction of $70,760.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,872 shares of company stock worth $2,302,672. 7.80% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Analysts Offer Predictions for United Therapeutics Co.’s Q2 2018 Earnings (UTHR)” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/01/03/analysts-offer-predictions-for-united-therapeutics-co-s-q2-2018-earnings-uthr.html.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply